A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders

Show full item record



Permalink

http://hdl.handle.net/10138/335926

Citation

GEMSTONE Working Grp 3 COST Action , Formosa , M M , Bergen , D J M , Gregson , C L & Mäkitie , O 2021 , ' A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders ' , Frontiers in Endocrinology , vol. 12 , 709711 . https://doi.org/10.3389/fendo.2021.709711

Title: A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders
Author: GEMSTONE Working Grp 3 COST Action; Formosa, Melissa M.; Bergen, Dylan J. M.; Gregson, Celia L.; Mäkitie, Outi
Contributor: University of Helsinki, HUS Children and Adolescents
Date: 2021-08-13
Language: eng
Number of pages: 24
Belongs to series: Frontiers in Endocrinology
ISSN: 1664-2392
URI: http://hdl.handle.net/10138/335926
Abstract: Genetic disorders of the skeleton encompass a diverse group of bone diseases differing in clinical characteristics, severity, incidence and molecular etiology. Of particular interest are the monogenic rare bone mass disorders, with the underlying genetic defect contributing to either low or high bone mass phenotype. Extensive, deep phenotyping coupled with high-throughput, cost-effective genotyping is crucial in the characterization and diagnosis of affected individuals. Massive parallel sequencing efforts have been instrumental in the discovery of novel causal genes that merit functional validation using in vitro and ex vivo cell-based techniques, and in vivo models, mainly mice and zebrafish. These translational models also serve as an excellent platform for therapeutic discovery, bridging the gap between basic science research and the clinic. Altogether, genetic studies of monogenic rare bone mass disorders have broadened our knowledge on molecular signaling pathways coordinating bone development and metabolism, disease inheritance patterns, development of new and improved bone biomarkers, and identification of novel drug targets. In this comprehensive review we describe approaches to further enhance the innovative processes taking discoveries from clinic to bench, and then back to clinic in rare bone mass disorders. We highlight the importance of cross laboratory collaboration to perform functional validation in multiple model systems after identification of a novel disease gene. We describe the monogenic forms of rare low and high rare bone mass disorders known to date, provide a roadmap to unravel the genetic determinants of monogenic rare bone mass disorders using proper phenotyping and genotyping methods, and describe different genetic validation approaches paving the way for future treatments.
Subject: bone mass
monogenic bone disorders
gene variants
functional validation
drug discovery
GEMSTONE
skeletal dysplasia
AUTOSOMAL-DOMINANT OSTEOPETROSIS
ALBERS-SCHONBERG-DISEASE
MOUSE MODELS
OSTEOGENESIS IMPERFECTA
BUCHEM-DISEASE
OSTEOPOROSIS
MUTATION
SCLEROSTEOSIS
LIMITATIONS
DEFICIENCY
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fendo_12_709711.pdf 14.60Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record